Bloomberg reports that British pharmaceutical company GlaxoSmithKline is planning to produce 1 billion doses of adjuvants to enhance the anti-Covid-19 vaccine.
According to a statement by Glaxo on May 28, adjuvants can reduce the amount of vaccine needed per dose, help increase the number of people receiving Covid-19 vaccine and create long-term immunity.
In April, the British drugmaker agreed to provide technology to develop a test vaccine with French pharmaceutical giant Sanofi. Glaxo is one of dozens of companies racing to develop vaccines. Vaccine will be key to stopping the Covid-19 epidemic and reopening the global economy. To date, the number of deaths due to Covid-19 has exceeded 350,000.
The London-based company says it plans to produce excipients in Europe, Canada and the United States. They started production immediately after reviewing the supply network and realized that they could increase capacity.
Glaxo does not expect to make money from the Covid-19 vaccine and will invest any profits to support research and preparation for the long-term pandemic.
Last month, CEO Emma Walmsley announced the goal of the agreement with Sanofi was to produce hundreds of millions of doses of vaccine each year by the end of next year. In agreement with the Alliance for Disease Preparedness Innovation, Glaxo also agreed to share the method with other vaccine developers.
“We will need more than one vaccine to deal with the global pandemic,” said Roger Conner, Glaxo’s vaccine development director.